Prompt treatment for primary Sjögren’s disease in patients who develop cerebral infarction (CI) helps promote neurological recovery and reduce the risk of stroke recurrence, a new study found.
The retrospective study showed the recurrence rate of CI was 0% in the group treated with immunosuppressants but 33.3% in the non-treatment group, while the odds of achieving a favourable prognosis in the treatment group were 7.5 times higher than in the non-treatment group.
Sjögren’s disease screening is necessary for CI patients, authors noted. “Prompt immunomodulatory therapies for Sjögren’s disease will facilitate neurofunctional recovery and reduce the recurrence of CI disease,” they concluded.
The study was published in Nature Scientific Reports.
